Cited 0 times in
Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2024-01-03T00:43:29Z | - |
dc.date.available | 2024-01-03T00:43:29Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197353 | - |
dc.description.abstract | Introduction: Pegylated granulocyte colony-stimulating factor (G-CSF) has been widely used for preventing febrile neutropenia in various types of cancer treatment. In the present study, we prospectively evaluated the safety and efficacy of pegfilgrastim as a primary prophylaxis of febrile neutropenia and infection among patients with relapsed refractory multiple myeloma (RRMM) treated with pomalidomide-based regimens. Methods: Thirty-three patients with RRMM who received pomalidomide and dexamethasone (Pd) with or without cyclophosphamide (PCd) were enrolled in this study. Twenty-eight patients were treated with PCd and 5 patients were treated with Pd. All patients were given pegfilgrastim subcutaneously with a single administration performed on the first day of each cycle as primary prophylaxis until the fourth cycle. Results: The median age of the patients was 75 (range 56-85), and the median prior line of therapy was 2 (range 2-6). Seventeen patients (51.5%) had any grade of neutropenia and 20 (60.6%) had any grade of thrombocytopenia before starting pomalidomide treatment. During the 4 cycles of treatment, grade 3 or more neutropenia occurred in 17 patients (51.5%), and 4 (12.1%) experienced grade 3 or more febrile neutropenia. Grade 3 or more infections occurred in 5 patients (15.2%). Interestingly, the patients with markedly increased ANC of more than 2 x 109/L compared to baseline ANC after 7 days of pegfilgrastim at 1st cycle of treatment showed a significantly lower incidence of grade 3-4 neutropenia. The most common adverse event of pegfilgrastim was fatigue, and all the adverse events caused by pegfilgrastim were grade 1 or 2. And there was no significant change in the immune cell population and cytokines during the administration of pegfilgrastim. Discussion: Considering that this study included elderly patients with baseline neutropenia, pegylated G-CSF could be helpful to prevent severe neutropenia, febrile neutropenia, or infection in patients with RRMM. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Frontiers Research Foundation | - |
dc.relation.isPartOf | FRONTIERS IN ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ga-Young Song | - |
dc.contributor.googleauthor | Je-Jung Lee | - |
dc.contributor.googleauthor | Joon Ho Moon | - |
dc.contributor.googleauthor | Dajung Kim | - |
dc.contributor.googleauthor | Min Kyoung Kim | - |
dc.contributor.googleauthor | Hyo Jung Kim | - |
dc.contributor.googleauthor | Yeung-Chul Mun | - |
dc.contributor.googleauthor | Won-Sik Lee | - |
dc.contributor.googleauthor | Young Rok Do | - |
dc.contributor.googleauthor | Jae Hoon Lee | - |
dc.contributor.googleauthor | Sung-Hoon Jung | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.identifier.doi | 10.3389/fonc.2023.1209110 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J03512 | - |
dc.identifier.eissn | 2234-943X | - |
dc.identifier.pmid | 37965454 | - |
dc.subject.keyword | febrile neutropenia | - |
dc.subject.keyword | multiple myeloma | - |
dc.subject.keyword | pegfilgrastim | - |
dc.subject.keyword | pomalidomide | - |
dc.subject.keyword | prophylaxis | - |
dc.contributor.alternativeName | Kim, Jin Seok | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 13 | - |
dc.citation.startPage | 1209110 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, Vol.13 : 1209110, 2023-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.